Inflammation

Cell culture studies suggest combined inhibition of BRD4 and HDAC could help treat type I interferon-driven diseases. In fibroblasts from patients deficient in the type I interferon regulators ISG15 or USP18, a tool compound BRD4 inhibitor plus the HDAC inhibitor Istodax romidepsin decreased levels of disease markers, including levels of MX1 mRNA and RSAD2 mRNA, compared with either agent alone. Next steps could include identifying and testing BRD4 inhibitors in combination with Istodax in animal models of type I interferon-driven diseases.

Celgene Corp. markets Istodax to treat lymphoma and has the compound in Phase II testing for solid tumors...